TY - JOUR
T1 - Treatment interruption and discontinuation in radiotherapy for rectal cancer
AU - Lebwohl, Benjamin
AU - Ballas, Leslie
AU - Cao, Yin
AU - Chan, Galant
AU - Grossman, Reuven
AU - Sherr, David L.
AU - Woodhouse, Shermian
AU - Neugut, Alfred I.
N1 - Funding Information:
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. B. Lebwohl is supported by a fellowship from the National Cancer Institute (T32-CA095929).
PY - 2010
Y1 - 2010
N2 - Radiotherapy with chemotherapy for rectal cancer reduces local recurrence risk. Of 113 patients (59 male, 54 female) undergoing treatment at New York Presbyterian Hospital, 1998-2007, 6 discontinued radiotherapy; all were female. Females were also more likely to have a treatment interruption (35% vs 12%, p = .004). Other factors associated with treatment interruption included adjuvant versus neoadjuvant therapy (OR 14.08, 95%CI 1.55-127.87), use of capecitabine versus 5-fluorouracil (OR 75.90, 95%CI 3.33>999), and development of any adverse event (OR 20.66, 95%CI 1.76-242.12). While radiotherapy discontinuation was uncommon in our cohort, for unknown reasons, females were more likely to discontinue or interrupt treatment.
AB - Radiotherapy with chemotherapy for rectal cancer reduces local recurrence risk. Of 113 patients (59 male, 54 female) undergoing treatment at New York Presbyterian Hospital, 1998-2007, 6 discontinued radiotherapy; all were female. Females were also more likely to have a treatment interruption (35% vs 12%, p = .004). Other factors associated with treatment interruption included adjuvant versus neoadjuvant therapy (OR 14.08, 95%CI 1.55-127.87), use of capecitabine versus 5-fluorouracil (OR 75.90, 95%CI 3.33>999), and development of any adverse event (OR 20.66, 95%CI 1.76-242.12). While radiotherapy discontinuation was uncommon in our cohort, for unknown reasons, females were more likely to discontinue or interrupt treatment.
KW - Colorectal & anal cancer
KW - Outcomes research
KW - Radiation oncology
UR - http://www.scopus.com/inward/record.url?scp=77149171513&partnerID=8YFLogxK
U2 - 10.3109/07357900903476786
DO - 10.3109/07357900903476786
M3 - Article
C2 - 20073579
AN - SCOPUS:77149171513
SN - 0735-7907
VL - 28
SP - 289
EP - 294
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -